Navigation Links
Amgen and Peregrine Under StockCall Scrutiny: Pharma Stocks Deal with Drug Developments and Patents
Date:2/6/2013

of its revenue from Neupogen franchise. However, the drug would go off patent protection by the end of 2013 and the loss of exclusivity is expected to affect Amgen. Neupogen faces stiff competition from the companies like Novartis in the markets outside of the U.S. and these competing companies may launch their products in the U.S., causing further damage. However, the company has somewhat strong drug candidates including AMG145, a cholesterol drug candidate.

Amgen stock grew over 25 percent in the past 12 months. It also offers good dividend yield of 2.17 percent. The company is likely to increase its dividend in the future, thus offering good returns to the investors. Amgen is also growing through acquisitions as it recently completed the purchase of Icelandic company decode Genetics.

Peregrine Struggles with Cancer Drug Development

Peregrine Pharmaceuticals Inc. specializes in developing therapies for viral infections. It also develops treatments for cancers. It is currently engaged in developing treatment for non-small cell lung cancer. If successful, the company will make big fortunes as non-small cell lung cancer accounts for about 80 percent of lung cancer cases. However, the company does not have very solid track record. The drug candidate bavituximab has been controversial as it led to the stock's massive tumble in September 2012. Sign up to download the free technical analysis on Peregrine Pharmaceuticals at

http://www.StockCall.com/PPHM020613.pdf  

Peregrine is a small company with the market capitalization of less than $300 million. The stock is quite volatile as well. The company is currently looking to get past the phase II for bavituximab. Overall, the stock may be held if it is already in your portfolio. On the upside, the stock is currently trading about 50 percent below its 52-week high, thus in case of positive news on its
'/>"/>

SOURCE StockCall.com
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Amgen to Acquire Mustafa Nevzat, a Leading Privately Held Turkish Pharmaceutical Company
2. Four Californians Selected As Breakaway from Cancer® Champions To Be Honored During Amgen Tour of California
3. Amgen to Present at the Baird Growth Stock Conference
4. Amgen To Provide Testimony At FDA Stakeholder Hearing On Biosimilars
5. Amgens BiTE® Antibody Blinatumomab (AMG 103) Achieved High Rate of Complete Response in Adult Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
6. Amgen Announces Top-Line Results Of Phase 3 Sensipar®/Mimpara® EVOLVE™ Trial
7. Amgen Completes Acquisition of Mustafa Nevzat Pharmaceuticals
8. Amgen Completes Acquisition of KAI Pharmaceuticals
9. Amgens Second Quarter 2012 Revenues Increased 13 Percent To $4.5 Billion And Adjusted Earnings Per Share (EPS) Increased 34 Percent To $1.83
10. Amgen Announces Termination Of Ganitumab Phase 3 Study For Futility In Metastatic Pancreatic Cancer
11. Amgen To Present At The Baird Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX), a clinical-stage drug development ... announced that J.J. Finkelstein , chief executive officer ... at two upcoming investor conferences. Mr. ... Annual Microcap Conference on Thursday May 28, 2015 in ... am EDT.  A webcast will be available at the ...
(Date:5/22/2015)... -- The Mesothelioma Victims Center is incredibly passionate about ... best possible compensation, and they are also extremely focused ... caused by exposure to asbestos or their family ... options such as a recent possible medical breakthrough. For ... anytime at 866-714-6466. http://MesotheliomaVictimsCenter.Com ...
(Date:5/22/2015)... May 22, 2015 Research and Markets ... of the "Latest Regulations on Pharmaceutical International ... their offering. This is first time ... guidance on international multi-center clinical trials of drugs ... begun to be implemented on March 1, 2015. ...
Breaking Medicine Technology:RegeneRx to Present at 2 Investor Conferences 2RegeneRx to Present at 2 Investor Conferences 3Mesothelioma Victims Center Calls Attention to a Recent Medical Article About a New Drug That Could Slow the Progression of Mesothelioma and Allow People to Live Longer 2Mesothelioma Victims Center Calls Attention to a Recent Medical Article About a New Drug That Could Slow the Progression of Mesothelioma and Allow People to Live Longer 3Mesothelioma Victims Center Calls Attention to a Recent Medical Article About a New Drug That Could Slow the Progression of Mesothelioma and Allow People to Live Longer 4Mesothelioma Victims Center Calls Attention to a Recent Medical Article About a New Drug That Could Slow the Progression of Mesothelioma and Allow People to Live Longer 52015 Regulations on Pharmaceutical International Multi-Center Clinical Trials in China 2
(Date:5/26/2015)... Beginning this fall, Boston University will ... Master of Social Work (MSW) program . Already available ... River Campus, the online option will be offered starting ... option is open to applicants holding an undergraduate social ... Education. Students entering the program will be granted 22 ...
(Date:5/26/2015)... Dearborn Ear, Nose & Throat in Dearborn, MI ... and improved website to better showcase their Detroit area ... Nose & Throat’s new website utilizes an innovative and ... seamlessly on any desktop computer, tablet or mobile device. ... Nose & Throat website include an innovative design ...
(Date:5/25/2015)... 2015 The report “Liver Failure ... on the therapeutic development for Liver Failure. The ... and MOAs to produce first-in-class and best-in-class products. ... Liver Failure with 22 market data tables and ... at http://www.rnrmarketresearch.com/liver-failure-pipeline-review-h1-2015-market-report.html . , Companies discussed ...
(Date:5/25/2015)... (PRWEB) May 26, 2015 Author Vincent N. ... of people today are overweight, and many of them aren’t ... He also knows that most people don’t realize the dangers ... hazards and man-made toxins that exist. There is ... realize exactly how serious tobacco is.” , In “ A ...
(Date:5/25/2015)... City, NY (PRWEB) May 26, 2015 ... honors Laquanis Hooker as a 2015-2016 inductee into its ... recognized with this prestigious distinction for leadership in dentistry. ... professional women, boasting more than 700,000 members and over ... welcome Laquanis into this exceptional group of professional women,” ...
Breaking Medicine News(10 mins):Health News:Boston University to Offer Online Master of Social Work Advanced Standing Option 2Health News:Boston University to Offer Online Master of Social Work Advanced Standing Option 3Health News:Dearborn Ear, Nose & Throat Launches ‘Responsive Design’ Website 2Health News:Liver Failure Pipeline Assessment and Key Players Review H1 2015 Market Research Report Available at RnRMarketResearch.com 2Health News:Liver Failure Pipeline Assessment and Key Players Review H1 2015 Market Research Report Available at RnRMarketResearch.com 3Health News:Liver Failure Pipeline Assessment and Key Players Review H1 2015 Market Research Report Available at RnRMarketResearch.com 4Health News:New Book Reveals ‘A Doctor’s Prescription for Longevity and Survival’ 2Health News:New Book Reveals ‘A Doctor’s Prescription for Longevity and Survival’ 3Health News:National Association of Professional Women Inducts Dr. Laquinas Hooked, D.D.S. of General Dentist, Into its VIP Professional Woman of the Year Circle 2
... , THURSDAY, Oct. 28 (HealthDay News) -- The ... among Americans diagnosed with diabetes fell 35 percent between 1996 ... rate of end-stage kidney disease, also known as end-stage renal ... to about 199 per 100,000 people during that time. The ...
... the immune system and nervous system turn Neuroimmunology into ... Between October 26th and 30th takes place in Sitges ... the International Society of Neuroimmunology. This event highlights the ... to new technologies, but also highlights the long road ...
... recently was awarded a two-year, $2.4 million grant ... Commission (Tobacco Commission) to expand the breadth of ... state-of-the-art clinical research and cancer specialist delivery system. ... communities across Virginia, such as in the Lynchburg, ...
... -- Two-thirds of preschoolers in the United States are ... day of screen time from television, computers, video games ... a new study has found. Researchers from Seattle ... at the daily screen time of nearly 9,000 preschool-age ...
... , WEDNESDAY, Oct. 27 (HealthDay News) -- ... at increased risk for obesity in adulthood, a new ... of the symptoms of ADHD -- such as inattention, ... being obese, according to researchers from Duke University Medical ...
... 2010 -- The American Academy of Pediatrics (AAP) recommends that ... video games to 2 hours per day for preschool-age children. ... Journal of Pediatrics , researchers found that many children ... at child care, with 66% exceeding the recommended daily amount. ...
Cached Medicine News:Health News:Drop Seen in Rate of End-Stage Kidney Disease in Diabetics 2Health News:Multiple sclerosis will become a controlled disease like AIDS 2Health News:VCU Massey Cancer Center awarded $2.4 million grant from Virginia Tobacco Commission 2Health News:U.S. Preschoolers Getting Too Much Screen Time: Study 2Health News:Children with ADHD Symptoms at Higher Risk of Obesity 2Health News:New study suggests most preschool-age children exceed daily screen time recommendations 2
View Mex-2 is designed for out-patient surgery, hospital rounds and house calls....
Fiberoptic lightweight coaxial rotary headlight with variable spot....
It is a magnifying headlight perfect for all applications and procedures where clear magnification and a natural white light increase accuracy and productivity....
... It is powerful, ... very comfortable, soft, durable ... cushion pad, covered by ... wrap. Flexible headband easily ...
Medicine Products: